Lv71
4238 积分 2021-07-21 加入
Differentiation of stem-like CD4 + T cells modulates early effector responses in colorectal cancer
57分钟前
已完结
HB0025 With Chemotherapy for Advanced Non–Small Cell Lung Cancer
10天前
已关闭
HB0025 With Chemotherapy for Advanced Non–Small Cell Lung Cancer
10天前
已关闭
HB0025 With Chemotherapy for Advanced Non–Small Cell Lung Cancer
10天前
已关闭
HB0025 With Chemotherapy for Advanced Non–Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial
10天前
已关闭
Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China
14天前
已完结
Izalontamab brengitecan for HR+/HER2– breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial
14天前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
14天前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
14天前
已完结
Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial
29天前
已完结